Endo Inc. (NDOI)
OTCMKTS
· Delayed Price · Currency is USD
24.87
+0.37 (1.51%)
Jan 8, 2025, 4:00 PM EST
Endo Inc. Revenue
Endo Inc. had revenue of $426.51M in the quarter ending September 30, 2024, a decrease of -5.57%. This brings the company's revenue in the last twelve months to $1.79B, down -13.49% year-over-year. In the year 2023, Endo Inc. had annual revenue of $2.01B, down -13.25%.
Revenue (ttm)
1.79B
Revenue Growth
-13.49%
P/S Ratio
2.30
Revenue / Employee
610.84K
Employees
2,931
Market Cap
1.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.01B | -307.36M | -13.25% |
| Dec 31, 2022 | 2.32B | -674.33M | -22.53% |
| Dec 31, 2021 | 2.99B | 90.13M | 3.10% |
| Dec 31, 2020 | 2.90B | -11.29M | -0.39% |
| Dec 31, 2019 | 2.91B | -32.71M | -1.11% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 21.77M |
| Jun An Kang Group | 4.47M |
| BioStem Technologies | 210.49M |
Endo Inc. News
- 24 days ago - Endo Announces Publication of Peyronie's Disease Self-Assessment Screening App Article in Peer-Reviewed Translational Andrology and Urology - PRNewsWire
- 4 weeks ago - Endo Receives U.S. FDA Approval of Manufacturing Facility in Indore, India - PRNewsWire
- 5 weeks ago - Endo Launches ADRENALIN® Ready-to-Use Premixed Bag, the First and Only FDA-Approved, Manufacturer-Prepared Epinephrine Premixed IV Bag - PRNewsWire
- 7 weeks ago - John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum) - PRNewsWire
- 7 weeks ago - Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling - PRNewsWire
- 7 weeks ago - Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada - PRNewsWire
- 2 months ago - Endo International plc (ENDPQ) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial Expectations - PRNewsWire